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012.11.00Abstract Rheumatoid arthritis may be associated with an increased risk of hematological malig-
nancy. Increased lympho-proliferative malignancy in rheumatoid arthritis is often described; how-
ever an increased risk of leukemia is not a common ﬁnding. A few cases of rheumatoid arthritis
have been documented associated with chronic myeloid leukemia in the literature. We report a
new case.
Case presentation: A 36-year-old Moroccan female diagnosed as rheumatoid arthritis eight years
ago, was on remission under Methotrexate and prednisone. This therapy was stopped one year
before her admission at our hospital because of thrombopenia and anemia. She had polyarthritis
ﬂare. The physical examination found splenomegaly, hepatomegaly, and skin lesions at the trunk
and limbs. Peripheral blood ﬁndings, peripheral smear and bone marrow aspiration diagnosed mye-
loid leukemia in a blastic accelerated phase with negative Philadelphia chromosome. The skin
lesions were diagnosed as pyoderma gangrenosum (skin biopsy). She received oral prednisone
and chemotherapy (Cytarabine and 6-Mercaptopurine). She had a complete response on the skin
lesions, partial regression of splenomegaly, and improvement of her hematologic disorders. Unfor-
tunately the patient died from septic shock after two weeks of post-chemotherapy pancytopenia.1374455; fax: +212 535613713 (S. Mansouri), tel.:+ 212 6 41 99 14 15 (W. Bono).
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Figure 1 Ulcerative pyoderma gan
patient with RA associated with CM
2 S. Mansouri et al.Conclusion: We report an unusual case of rheumatoid arthritis complicated by chronic myeloid
leukemia associated with pyoderma gangrenosum. It is unclear whether the development of chronic
myeloid leukemia in the patient with rheumatoid arthritis occurs by chance alone, is due to the
underlying disease, or is facilitated by drugs. Whatever the cause is, it should be kept in mind that
chronic myeloid leukemia may develop in the course of rheumatoid arthritis.
 2012 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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Rheumatoid arthritis (RA) is a systemic inﬂammatory disease
that may be associated with an increased risk of hematological
malignancy (most often lympho-proliferative disorders), per-
haps as a result of RA itself or its treatments [1,2]. We describe
through this article an unusual case of a patient with long-
standing RA requiring Disease-Modifying Antirheumatic
Drugs (DMARDS) (Methotrexate), who developed a myelo-
proliferative malignancy (chronic myeloid leukemia) associ-
ated with pyoderma gangrenosum (PG).
2. Case report
A 36-year-old Moroccan female diagnosed as a sero-positive
RA (fulﬁlling the criteria of the American College of Rheuma-
tology 1987 [3]) 8 years ago, was on remission under the combi-
nation of Methotrexate (15 mg weekly) and prednisone 10 mg
per day. This therapy was stopped one year before her admis-
sion at our hospital because of thrombopenia and anemia.
She had polyarthritis ﬂare. Disease activity was assessed by
DAS 28 [4] which was at 7,07 (tenderness joints count = 28,
swollen joints count = 0, ESR = 87 mm, global score =
70%). Her rheumatoid factor was positive at 52 U/ml (0–
14 UI/ml), anti-citrulline peptide antibodies were positive at
185 UI/ml (<5 UI/ml), antinuclear antibodies and extractable
nuclear antigen were negative, ESR was 87 mm (ﬁrst hour), and
C-reactive protein was 32 mg/l.
The physical examination found splenomegaly, hepatomeg-
aly and bullous and vesiculo-pustular skin lesions at the trunk
and limbs (Figs. 1 and 2).
We thought about drug toxicity, but peripheral blood
ﬁndings were: anemia with hemoglobin at 9,3 g/dl and throm-grenosum (abdomen) in a
L.bopenia with platelets at 53000/mm3. The WBCs were high at
50 · 103/mm3 (neutrophils: 28990/mm3, monocytes: 14020/
mm3). Peripheral smear revealed 9% blasts, 7% promyelo-
cytes, 17% myelocytes, 8% metamyelocytes, 25% neutrophils,
1% eosinophils, 8% lymphocytes, and 6% monocytes. Bone
marrow aspiration diagnosed myeloid leukemia in a blastic
accelerated phase with negative Philadelphia chromosome.
The skin lesions were diagnosed as pyoderma gangrenosum
(PG) when the patient underwent skin biopsy.
We consider that she had an unusual secondary hematolog-
ical malignancy (CML) with skin assessment (PG). So she re-
ceived oral prednisone (1 mg/kg/day) for two weeks, and at the
same time, she started chemotherapy combining a low dose of
Cytarabine (100 mg/m2/day) and 6-Mercaptopurine (1,5 mg/
kg/day).
The results were ﬁrst a complete response to the skin le-
sions, partial regression of splenomegaly, and improvement
of her hematologic disorders (WBC= 9800/mm3) after one
week of treatment. Unfortunately the patient died from septic
shock after two weeks of post-chemotherapy pancytopeniaFigure 2 Bullous pyoderma gangrenosum (legs) in a patient with
RA associated with CML.
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3. Discussion
Increased hematological malignancies are well recognized in
patients with RA, but there is disagreement about which sub-
types occur with a consistent description of lymphoprolifera-
tive malignancies. Persistent lymphocytes activation, with
dysregulation of B cell proliferation in RA, can induce malig-
nant transformation, in case of a chronic disease, or advanced
age, or immunosuppressive drugs using or both [1,5–7]. More
recent reviews have discussed the role of high inﬂammatory
disease activity, Epstein-Barr virus infection. Methotrexate
(MTX) treatment may be a risk factor for lymphoma in pa-
tients with RA. A study of the distribution of lymphoma sub-
types in patients with RA who had received MTX found an
increased incidence of diffuse large B cell lymphoma: 67%
[1,8,9].
However an increased risk of leukemia in patients with RA is
not a common ﬁnding. Chronic myelogenous leukemia (CML)
is a disease characterized by an overproduction of cells of the
granulocytic, especially the neutrophilic series and occasionally
the monocytic series, leading to marked splenomegaly and very
highwhite blood cell counts. There is no consensus on the risk of
this hematological disease in RA. A few cases of RA have been
documented associated with CML in the literature, in which a
variety of interactions have been described between these 2 dis-
eases [2,9–11]. There are some reports regarding the relationship
between the low dose of MTX (<20 mg weekly) and the devel-
opment of leukemia in RA. The possibility of the side effect of
MTX as a cause of CML can be evoked, because of long-term
use. We experienced a case of CML (36-year-old woman) asso-
ciated with sero-positive RA who was treated with low dose of
MTX (15 mg weekly for 6 years), and steroid drugs. She was
diagnosed CML after 7 years of therapy. Dubin Kerr et al. re-
ported a similar case in a patient with sero-positive RA who
developed CML after short-term low-dose use of MTX
[2,9,10]. Miyachi et al. reported the case of an 80-year-old
man who developed CML after a 5-year history of RA [2,11].
Soner Senel et al. reported the fourth patient in English litera-
ture who was diagnosed with CML after RA treated with
MTX. Some studies suggest that MTX increases this risk of
hematologic proliferative malignancies [1,2,5,7,12], whereas
others do not [2,13]. Although MTX treatment may be a risk
factor for CML in patients with RA, there is evidence that
RA itself may be associated with increased hematological malig-
nancy. An explanation may be that a persistent immune stimu-
lation in RA, disease chronicity, and high inﬂammatory disease
activity participate in the development of CML. It is unclear
whether the development of CML in patient with RA occurs
randomly, or because of the underlying disease, or it is facili-
tated by drugs. Whatever the cause is, it should be kept in mind
that CML may be developed in the course of RA. Our patient
presented sero-positive RA since 2004, was treated with MTX
for 6 years and has developed a CML after 7 years of treatment.
But it remains difﬁcult to determine whether the development of
CML is caused by the disease itself or facilitated by immunosup-
pressive treatment.
This case report is consistent with the observation of CML
in a patient with sero-positive RA associated with pyodermagangrenosum (PG). PG is a rare neutrophilic dermatosis that
can be associated with other medical illnesses (50% of affected
patients) like systemic lupus erythematosus (37%), inﬂamma-
tory bowel disease (15%), and hematological disease especially
myelogenous leukemia [14,15]. Uniquely interesting is that our
patient presented an atypical PG. Characteristic feature of this
atypical PG is that it begins as bulla and it is superﬁcial. Pa-
tients with this type of PG develop painful rapidly enlarging
bullous lesion which becomes superﬁcially erosive and then
ulcerative [14,16,17]. High dose of corticosteroids (1 mg/kg/
day) is usually the ﬁrst line therapy until lesion is healed, but
most cases are resistant to steroids. The presence of these le-
sions is an indicator that the patient with leukemia has a poor
prognosis [14,18]. The pathogenesis and the link between PG
and leukemia are poorly understood. Leukocyte colony stimu-
lating or other bone marrow factors, as well as chemotherapy
might play a role in the development of the symptoms.
In conclusion, rheumatoid arthritis may be associated with
an increased risk of hematological malignancy. Increased lym-
pho-proliferative malignancy in rheumatoid arthritis is often
described; however an increased risk of leukemia is not a com-
mon ﬁnding. DMARDS in RA should be chosen reasonably.
Methotrexate, yes, but for how long? Should we stop it? These
are questions that rheumatologists should ask to have re-
sponses in a large cohort of patients with a long follow-up.Conﬂict of interests
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